Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months for bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumourAstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its